Search

Your search keyword '"Alvarado, Yesid"' showing total 1,137 results
Start Over Author "Alvarado, Yesid"
1,137 results on '"Alvarado, Yesid"'

1. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma

Author

Ravandi, Farhad, Senapati, Jayastu, Jain, Nitin, Short, Nicholas J., Kadia, Tapan, Borthakur, Gautam, Konopleva, Marina, Wierda, William, Huang, Xuelin, Maiti, Abhishek, Issa, Ghayas, Balkin, Hayley, Garris, Rebecca, Ferrajoli, Alessandra, Garcia-Manero, Guillermo, Alvarado, Yesid, Kebriaei, Partow, Jabbour, Elias, and Kantarjian, Hagop M.

Published
2024
Full Text
View/download PDF

2. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Author

Bouligny, Ian M., Montalban-Bravo, Guillermo, Sasaki, Koji, Daver, Naval, Jabbour, Elias, Alvarado, Yesid, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Pemmaraju, Naveen, Kadia, Tapan, Masarova, Lucia, Takahashi, Koichi, Andreeff, Michael, Bazinet, Alexandre, Yang, Hui, Kanagal, Rashmi, Pierce, Sherry, Meyer, Meghan, Huang, Xuelin, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

5. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

Author

Kantarjian, Hagop, Haddad, Fadi G, Jain, Nitin, Sasaki, Koji, Short, Nicholas J, Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Jorgensen, Jeffrey, Khouri, Issa, Kebriaei, Partow, Alvarado, Yesid, Kadia, Tapan, Paul, Shilpa, Garcia-Manero, Guillermo, Dabaja, Bouthaina, Yilmaz, Musa, Jacob, Jovitta, Garris, Rebecca, O’Brien, Susan, Ravandi, Farhad, and Jabbour, Elias

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Pediatric Cancer, Stem Cell Research, Hematology, Childhood Leukemia, Cancer, Pediatric, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Humans, Antibodies, Bispecific, Cardiovascular Diseases, Inotuzumab Ozogamicin, Methotrexate, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Salvage Therapy, Blinatumomab, Chemo-immunotherapy, Inotuzumab, Outcome, Philadelphia-negative ALL, Salvage, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

BackgroundHistorically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-intensity mini-Hyper-CVD chemotherapy with inotuzumab ozogamicin in this setting.MethodsMini-Hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 83% dose reduction) was combined with inotuzumab during the first 4 courses. From Patient #68 and onwards, inotuzumab was given in reduced and fractionated doses, and blinatumomab was added sequentially for 4 courses. Maintenance therapy with prednisone, vincristine, 6-mercaptopurine and methotrexate was given for 12 courses, and blinatumomab for 4 additional courses.ResultsAmong 110 patients (median age, 37 years) treated, 91 (83%) responded (complete response, 69 patients, 63%). Measurable residual disease negativity was documented in 75 patients (82% of responders). Fifty-three patients (48%) received allogeneic stem cell transplantation (SCT). Hepatic sinusoidal obstruction syndrome occurred in 9/67 patients (13%) on the original inotuzumab schedule and in 1/43 (2%) on the modified schedule. With a median follow-up of 48 months, the median overall survival (OS) was 17 months, and the 3 year OS was 40%. The 3 year OS was 34% with mini-Hyper-CVD plus inotuzumab and 52% with additional blinatumomab (P = 0.16). By landmark analysis at 4 months, the 3 year OS was 54%, similar between patients who did or did not receive allogeneic SCT.ConclusionLow-intensity mini-Hyper-CVD plus inotuzumab with or without blinatumomab showed efficacy in patients with relapsed-refractory ALL, with better survival after the addition of blinatumomab. Trial registration The trial was registered on clinicaltrials.gov with the identifier NCT01371630.

Published
2023

8. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Author

Bazinet, Alexandre, Garcia-Manero, Guillermo, Short, Nicholas, Alvarado, Yesid, Bataller, Alex, Abuasab, Tareq, Islam, Rabiul, Montalbano, Kathryn, Issa, Ghayas, Maiti, Abhishek, Yilmaz, Musa, Jain, Nitin, Masarova, Lucia, Kornblau, Steven, Jabbour, Elias, Montalban-Bravo, Guillermo, Rausch, Caitlin R, Pierce, Sherry, DiNardo, Courtney D, Kadia, Tapan, Daver, Naval, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2024
Full Text
View/download PDF

9. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Author

Bataller, Alex, Montalban-Bravo, Guillermo, Bazinet, Alexandre, Alvarado, Yesid, Chien, Kelly, Venugopal, Sangeetha, Ishizawa, Jo, Hammond, Danielle, Swaminathan, Mahesh, Sasaki, Koji, Issa, Ghayas C, Short, Nicholas J, Masarova, Lucia, Daver, Naval G, Kadia, Tapan M, Colla, Simona, Qiao, Wei, Huang, Xuelin, Kanagal-Shamanna, Rashmi, Hendrickson, Stephany, Ravandi, Farhad, Jabbour, Elias, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

10. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Author

Hammond, Danielle, Loghavi, Sanam, Wang, Sa A., Konopleva, Marina Y., Kadia, Tapan M., Daver, Naval G., Ohanian, Maro, Issa, Ghayas C., Alvarado, Yesid, Short, Nicholas J., Sasaki, Koji, Pemmaraju, Naveen, Montalban-Bravo, Guillermo, Lachowiez, Curtis A., Maiti, Abhishek, Garcia-Manero, Guillermo, Jabbour, Elias J., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Pierce, Sherry R., Kantarjian, Hagop M., and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

13. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Author

DiNardo, Courtney D., Venugopal, Sangeetha, Lachowiez, Curtis, Takahashi, Koichi, Loghavi, Sanam, Montalban-Bravo, Guillermo, Wang, Xuemei, Carraway, Hetty, Sekeres, Mikkael, Sukkur, Ameenah, Hammond, Danielle, Chien, Kelly, Maiti, Abhishek, Masarova, Lucia, Sasaki, Koji, Alvarado, Yesid, Kadia, Tapan, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop M., Patel, Bhumika, Dezern, Amy, Roboz, Gail, and Garcia-Manero, Guillermo

Published
2023
Full Text
View/download PDF

14. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Gonzalez, Graciela Nogueras, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2023
Full Text
View/download PDF

15. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Huang, Xuelin, Montalban-Bravo, Guillermo, Banerjee, Pinaki, Rezvani, Katayoun, Jiang, Xianli, Kim, Kun Hee, Kanagal-Shamanna, Rashmi, Khoury, Joseph D, Patel, Keyur, Kadia, Tapan M, Daver, Naval, Chien, Kelly, Alvarado, Yesid, Garcia-Manero, Guillermo, Issa, Ghayas C, Haddad, Fadi G, Kwari, Monica, Thankachan, Jennifer, Delumpa, Ricardo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2023
Full Text
View/download PDF

18. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Thompson, Philip A, Kadia, Tapan M, Ferrajoli, Alessandra, Huang, Xuelin, Yilmaz, Musa, Alvarado, Yesid, Patel, Keyur P, Garcia-Manero, Guillermo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2022
Full Text
View/download PDF

19. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

Author

Bazinet, Alexandre, Darbaniyan, Faezeh, Jabbour, Elias, Montalban-Bravo, Guillermo, Ohanian, Maro, Chien, Kelly, Kadia, Tapan, Takahashi, Koichi, Masarova, Lucia, Short, Nicholas, Alvarado, Yesid, Yilmaz, Musa, Ravandi, Farhad, Andreeff, Michael, Kanagal-Shamanna, Rashmi, Ganan-Gomez, Irene, Colla, Simona, Qiao, Wei, Huang, Xuelin, McCue, Deborah, Mirabella, Bailey, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2022
Full Text
View/download PDF

20. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

Author

Kantarjian, Hagop, Ravandi, Farhad, Short, Nicholas, Huang, Xuelin, Jain, Nitin, Sasaki, Koji, Daver, Naval, Pemmaraju, Naveen, Khoury, Joseph, Jorgensen, Jeffrey, Alvarado, Yesid, Konopleva, Marina, Garcia-Manero, Guillermo, Kadia, Tapan, Yilmaz, Musa, Bortakhur, Gautam, Burger, Jan, Kornblau, Steven, Wierda, William, DiNardo, Courtney, Ferrajoli, Alessandra, Jacob, Jovitta, Garris, Rebecca, OBrien, Susan, and Jabbour, Elias

Subjects
Academic Medical Centers, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Cancer Care Facilities, Cyclophosphamide, Dexamethasone, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin, Drug Administration Schedule, Female, Geriatric Assessment, Humans, Induction Chemotherapy, Inotuzumab Ozogamicin, Kaplan-Meier Estimate, Male, Middle Aged, Patient Safety, Patient Selection, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Proportional Hazards Models, Retrospective Studies, Single-Blind Method, Survival Analysis, Texas, Treatment Outcome, Vincristine
Abstract

BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimed to assess the activity and safety of inotuzumab ozogamicin in combination with low-intensity chemotherapy in older patients with acute lymphoblastic leukaemia. METHODS: We did a single-arm, phase 2 study at the MD Anderson Cancer Center (Houston, TX, USA). Eligible patients were aged 60 years or older and had newly diagnosed, Philadelphia chromosome-negative, acute lymphoblastic leukaemia, and an Eastern Cooperative Oncology Group performance status of 3 or lower. The induction chemotherapy regimen used was mini-hyper-CVD (a lower intensity version of the conventional hyper-CVAD). Odd-numbered cycles (1,3, 5, and 7) comprised intravenous cyclophosphamide (150 mg/m2 every 12 h on days 1-3) and oral or intravenous dexamethasone (20 mg per day on days 1-4 and days 11-14); no anthracycline was administered. Intravenous vincristine (2 mg flat dose) was given on days 1 and 8. Even-numbered cycles comprised intravenous methotrexate (250 mg/m2 on day 1) and intravenous cytarabine (0·5 g/m2 given every 12 h on days 2 and 3). Intravenous inotuzumab ozogamicin was given on day 3 of the first four cycles at the dose of 1·3-1·8 mg/m2 at cycle 1, followed by 1·0 -1·3 mg/m2 in subsequent cycles. Maintenance therapy with dose-reduced POMP (purinethol [6-mercaptopurine], oncovin [vincristine sulfate], methotrexate, and prednisone) was given for 3 years. The primary endpoint of this study was progression-free survival at 2 years. Analyses were by intention to treat. The study is ongoing, recruiting patients for an approved expansion phase with a modified treatment plan by protocol amendment. The trial is registered with ClinicalTrials.gov, number NCT01371630. FINDINGS: Between Nov 12, 2011, and April 22, 2017, 52 patients with a median age of 68 years (IQR 64-72) were enrolled. With a median follow-up of 29 months (IQR 13-48), 2-year progression-free survival was 59% (95% CI 43-72). The most frequent grade 3-4 adverse events were prolonged thrombocytopenia (42 [81%] patients), infections during induction (27 [52%]) and consolidation chemotherapy (36 [69%]), hyperglycaemia (28 [54%]), hypokalaemia (16 [31%]), increased aminotransferases (ten [19%]), hyperbilirubinaemia (nine [17%]), and haemorrhage (seven [15%]). Veno-occlusive disease occurred in four (8%) patients. Six (12%) patients died from adverse events that were deemed treatment related (five [10%] from sepsis and one [2%] from veno-occlusive disease). INTERPRETATION: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy is a safe and active first-line therapy option in older patients with newly diagnosed acute lymphoblastic leukaemia and could represent a new therapy for this population. Randomised, phase 3 trials to evaluate the efficacy of this combination compared with the current standard of care in this setting, combination chemotherapy without inotuzumab ozogamicin, are warranted. FUNDING: MD Anderson Cancer Center.

Published
2018

22. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia

Author

Jabbour, Elias, primary, Haddad, Fadi G., additional, Sasaki, Koji, additional, Carter, Bing Z., additional, Alvarado, Yesid, additional, Nasnas, Cedric, additional, Nasr, Lewis, additional, Masarova, Lucia, additional, Daver, Naval, additional, Pemmaraju, Naveen, additional, Short, Nicholas J., additional, Skinner, Jeffrey, additional, Kadia, Tapan, additional, Borthakur, Gautam, additional, Garcia‐Manero, Guillermo, additional, Ravandi, Farhad, additional, Issa, Ghayas C., additional, Andreeff, Michael, additional, and Kantarjian, Hagop, additional

Published
2024
Full Text
View/download PDF

23. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

Author

Kadia, Tapan M, Reville, Patrick K, Borthakur, Gautam, Yilmaz, Musa, Kornblau, Steven, Alvarado, Yesid, Dinardo, Courtney D, Daver, Naval, Jain, Nitin, Pemmaraju, Naveen, Short, Nicholas, Wang, Sa A, Tidwell, Rebecca S S, Islam, Rabiul, Konopleva, Marina, Garcia-Manero, Guillermo, Ravandi, Farhad, and Kantarjian, Hagop M

Published
2021
Full Text
View/download PDF

24. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Author

Lachowiez, Curtis A., Loghavi, Sanam, Furudate, Ken, Montalban-Bravo, Guillermo, Maiti, Abhishek, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas J., Chien, Kelly, Ohanian, Maro, Pierce, Sherry, Patel, Keyur P., Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Takahashi, Koichi, Konopleva, Marina Y., and DiNardo, Courtney D.

Published
2021
Full Text
View/download PDF

25. PUNITIVISMO, LEGÍTIMA DEFENSA Y SEGURIDAD CIUDADANA.

Author

López, Hernán Darío Orozco and Alvarado, Yesid Reyes

Subjects
CRIMINAL liability, SELF-defense, PUBLIC education, GOVERNMENT policy, WEAPONS, FOOD security, CRIMINALS
Abstract

Copyright of Derecho Penal y Criminologia is the property of Universidad Externado de Colombia, Departamento de Derecho Penal y Criminologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

27. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Author

DiNardo, Courtney D, Maiti, Abhishek, Rausch, Caitlin R, Pemmaraju, Naveen, Naqvi, Kiran, Daver, Naval G, Kadia, Tapan M, Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Issa, Ghayas C, Montalban-Bravo, Guillermo, Short, Nicholas J, Yilmaz, Musa, Bose, Prithviraj, Jabbour, Elias J, Takahashi, Koichi, Burger, Jan A, Garcia-Manero, Guillermo, Jain, Nitin, Kornblau, Steven M, Thompson, Philip A, Estrov, Zeev, Masarova, Lucia, Sasaki, Koji, Verstovsek, Srdan, Ferrajoli, Alessandra, Weirda, William G, Wang, Sa A, Konoplev, Sergej, Chen, Zhining, Pierce, Sherry A, Ning, Jing, Qiao, Wei, Ravandi, Farhad, Andreeff, Michael, Welch, John S, Kantarjian, Hagop M, and Konopleva, Marina Y

Published
2020
Full Text
View/download PDF

28. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

Author

Jabbour, Elias, Richard-Carpentier, Guillaume, Sasaki, Yuya, Konopleva, Marina, Patel, Keyur, Roberts, Kathryn, Gu, Zhaohui, Wang, Feng, Huang, Xuelin, Sasaki, Koji, Short, Nicholas J, Jain, Nitin, Ravandi, Farhad, Daver, Naval G, Kadia, Tapan M, Alvarado, Yesid, DiNardo, Courtney D, Issa, Ghayas C, Pemmaraju, Naveen, Garcia-Manero, Guillermo, Verstovsek, Srdan, Wang, Sa, Khoury, Joseph D, Jorgensen, Jeffrey, Champlin, Richard, Khouri, Issa, Kebriaei, Partow, Schroeder, Heather, Khouri, Maria, Mullighan, Charles G, Takahashi, Koichi, O'Brien, Susan M, and Kantarjian, Hagop

Published
2020
Full Text
View/download PDF

31. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Author

Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Takahashi, Koichi, Jabbour, Elias, Borthakur, Gautham, Pemmaraju, Naveen, Konopleva, Marina, Soltysiak, Kelly A., Pierce, Sherry R., Bueso-Ramos, Carlos E., Patel, Keyur P., Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2020
Full Text
View/download PDF

32. Prospective performance of the International Working Group 2023 and the International Prognostic Scoring System - Molecular in a phase II trial of guadecitabine in higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia

Author

Urrutia, Samuel, primary, Bose, Prithviraj, additional, Alvarado, Yesid, additional, Borthakur, Gautam, additional, Ravandi, Farhad, additional, Daver, Naval, additional, Pemmaraju, Naveen, additional, Jabbour, Elias, additional, Takahashi, Koichi, additional, Kadia, Tapan, additional, DiNardo, Courtney, additional, Kornblau, Steven, additional, Kanagal-Shamanna, Rashmi, additional, Huang, Xuelin, additional, Bodden, Kristy, additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2024
Full Text
View/download PDF

33. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Author

Jabbour, Elias, primary, Haddad, Fadi G., additional, Short, Nicholas J., additional, Senapati, Jayastu, additional, Jain, Nitin, additional, Sasaki, Koji, additional, Jorgensen, Jeffrey, additional, Wang, Sa A., additional, Alvarado, Yesid, additional, Wang, Xuemei, additional, DiNardo, Courtney, additional, Masarova, Lucia, additional, Kadia, Tapan, additional, Garris, Rebecca S., additional, Ravandi, Farhad, additional, and Kantarjian, Hagop, additional

Published
2024
Full Text
View/download PDF

34. EDITORIAL

Author

Orozco López, Hernán Darío and Reyes Alvarado, Yesid

Published
2023

35. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Author

Issa, Ghayas C., Kantarjian, Hagop M., Xiao, Lianchun, Ning, Jing, Alvarado, Yesid, Borthakur, Gautam, Daver, Naval, DiNardo, Courtney D., Jabbour, Elias, Bose, Prithviraj, Jain, Nitin, Kadia, Tapan M., Naqvi, Kiran, Pemmaraju, Naveen, Takahashi, Koichi, Verstovsek, Srdan, Andreeff, Micheal, Kornblau, Steven M., Estrov, Zeev, Ferrajoli, Alessandra, Garcia-Manero, Guillermo, Ohanian, Maro, Wierda, William G., Ravandi, Farhad, and Cortes, Jorge E.

Published
2020
Full Text
View/download PDF

36. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Author

Bose, Prithviraj, Verstovsek, Srdan, Cortes, Jorge E., Tse, Susan, Gasior, Yvonne, Jain, Nitin, Jabbour, Elias J., Estrov, Zeev, Alvarado, Yesid, DiNardo, Courtney D., Pemmaraju, Naveen, Kornblau, Steven M., Kadia, Tapan M., Daver, Naval G., Naqvi, Kiran, Short, Nicholas J., Masarova, Lucia, Villareal, John, Pierce, Sherry A., Nogueras-Gonzalez, Graciela, Huang, Xuelin, Garcia-Manero, Guillermo, Kantarjian, Hagop M., and Ravandi, Farhad

Published
2020
Full Text
View/download PDF

37. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure

Author

Chien, Kelly S., Rodriguez-Sevilla, Juan Jose, Alvarado, Yesid, Montalban-Bravo, Guillermo, Hammond, Danielle E., Swaminathan, Mahesh, Bazinet, Alexandre, Kimberley, Jacqueline, Bodden, Kristy, Schneider, Heather, Dong, Xiao Qin, Pierce, Sherry A., Huang, Xuelin, Jabbour, Elias J., Kantarjian, Hagop M., and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

38. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Author

Ravandi, Farhad, Assi, Rita, Daver, Naval, Benton, Christopher B, Kadia, Tapan, Thompson, Philip A, Borthakur, Gautam, Alvarado, Yesid, Jabbour, Elias J, Konopleva, Marina, Takahashi, Koichi, Kornblau, Steven, DiNardo, Courtney D, Estrov, Zeev, Flores, Wilmer, Basu, Sreyashi, Allison, James, Sharma, Padmanee, Pierce, Sherry, Pike, Allison, Cortes, Jorge E, Garcia-Manero, Guillermo, and Kantarjian, Hagop M

Published
2019
Full Text
View/download PDF

40. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Author

Short, Nicholas J, Kantarjian, Hagop M, Loghavi, Sanam, Huang, Xuelin, Qiao, Wei, Borthakur, Gautam, Kadia, Tapan M, Daver, Naval, Ohanian, Maro, Dinardo, Courtney D, Estrov, Zeev, Kanagal-Shamanna, Rashmi, Maiti, Abhishek, Benton, Christopher B, Bose, Prithviraj, Alvarado, Yesid, Jabbour, Elias, Kornblau, Steven M, Pemmaraju, Naveen, Jain, Nitin, Gasior, Yvonne, Richie, Mary Ann, Pierce, Sherry, Cortes, Jorge, Konopleva, Marina, Garcia-Manero, Guillermo, and Ravandi, Farhad

Published
2019
Full Text
View/download PDF

42. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients

Author

Jen, Wei-Ying, primary, Sasaki, Koji, additional, Rausch, Caitlin R., additional, DiNardo, Courtney D., additional, Kadia, Tapan M., additional, Yilmaz, Musa, additional, Borthakur, Gautam, additional, Alvarado, Yesid, additional, McCue, David, additional, Mccue, Deborah, additional, Kantarjian, Hagop M., additional, and Ravandi, Farhad, additional

Published
2023
Full Text
View/download PDF

44. Data from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., primary, Daver, Naval, primary, Wilson, Nathaniel R., primary, Ravandi, Farhad, primary, Garcia-Manero, Guillermo, primary, Kadia, Tapan, primary, DiNardo, Courtney D., primary, Jabbour, Elias, primary, Burger, Jan, primary, Short, Nicholas J., primary, Alvarado, Yesid, primary, Jain, Nitin, primary, Masarova, Lucia, primary, Issa, Ghayas C., primary, Qiao, Wei, primary, Khoury, Joseph D., primary, Pierce, Sherry, primary, Miller, Darla, primary, Sasaki, Koji, primary, Konopleva, Marina, primary, Bhalla, Kapil N., primary, Borthakur, Gautam, primary, and Pemmaraju, Naveen, primary

Published
2023
Full Text
View/download PDF

45. Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., primary, Daver, Naval, primary, Wilson, Nathaniel R., primary, Ravandi, Farhad, primary, Garcia-Manero, Guillermo, primary, Kadia, Tapan, primary, DiNardo, Courtney D., primary, Jabbour, Elias, primary, Burger, Jan, primary, Short, Nicholas J., primary, Alvarado, Yesid, primary, Jain, Nitin, primary, Masarova, Lucia, primary, Issa, Ghayas C., primary, Qiao, Wei, primary, Khoury, Joseph D., primary, Pierce, Sherry, primary, Miller, Darla, primary, Sasaki, Koji, primary, Konopleva, Marina, primary, Bhalla, Kapil N., primary, Borthakur, Gautam, primary, and Pemmaraju, Naveen, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., primary, Daver, Naval, primary, Wilson, Nathaniel R., primary, Ravandi, Farhad, primary, Garcia-Manero, Guillermo, primary, Kadia, Tapan, primary, DiNardo, Courtney D., primary, Jabbour, Elias, primary, Burger, Jan, primary, Short, Nicholas J., primary, Alvarado, Yesid, primary, Jain, Nitin, primary, Masarova, Lucia, primary, Issa, Ghayas C., primary, Qiao, Wei, primary, Khoury, Joseph D., primary, Pierce, Sherry, primary, Miller, Darla, primary, Sasaki, Koji, primary, Konopleva, Marina, primary, Bhalla, Kapil N., primary, Borthakur, Gautam, primary, and Pemmaraju, Naveen, primary

Published
2023
Full Text
View/download PDF

48. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Author

Venugopal, Sangeetha, Kantarjian, Hagop, Maiti, Abhishek, Short, Nicholas J., Montalban-Bravo, Guillermo, Alvarado, Yesid, Chien, Kelly, Kanagal-Shamanna, Rashma, Pemmaraju, Naveen, Daver, Naval, Kadia, Tapan, Borthakur, Gautam, Jabbour, Elias, and Garcia-Manero, Guillermo

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results